Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Research and Innovation Action · Running

ACCESS AD Advancing Clinical Care and Equity through Scalable Solutions in Alzheimer’s Disease diagnosis and treatment

Coordinator
Stichting Amsterdam Umc, Netherlands
Runs
1 January 2026 to 31 December 2030
Status
Running
EU funding
€20.2m
Total cost
€37.6m
Partners
36 organisations in 13 countries
Type
Research and Innovation Action
Grant agreement
101253010

What the project is doing

In the project's own words, from its summary on CORDIS.

Alzheimer’s disease (AD) is a growing public health challenge in Europe’s ageing population. While Disease Modifying Therapies (DMTs) bring new therapeutic potential, fragmented care pathways, unequal diagnostic access, and healthcare limitations threaten their effectiveness and scalability. The Access AD Project is a collaborative initiative that exemplifies the public-private partnership model, bringing together government agencies and private sector organizations to addresses this unmet need by translating advanced diagnostics and monitoring approaches—such as blood-based and imaging biomarkers, digital and AI tools—into coordinated, equitable, and scalable care across real-world clinical settings in Europe.

The project aims to ensure that every individual with AD can access timely, personalized, and cost-effective care, regardless of geography or socioeconomic status. ACCESS-AD builds on local, national, and EU-level efforts to create an integrated, pan-European framework for optimized AD care. The project will achieve: 1) establish robust coordination and governance to ensure efficient delivery and stakeholder alignment; 2) connect and expand fragmented clinical and research data through a shared platform, linking registries and initiatives across Europe; 3) reduce diagnostic access barriers by improving standardized imaging, blood-based, and digital biomarkers for clinical use; 4) develop AI-driven tools to support personalized treatment decisions; 5) generate harmonized real-world evidence on DMTs and emerging therapies; 6) assess health-economic, regulatory, and patient-reported impacts; 7) engage patients, professionals, and policymakers to ensure adoption and sustainability.

Aligned with IHI Call 9.2, ACCESS-AD unites and engages diverse healthcare stakeholders and integrates needs and perspectives of individuals affected by dementia to deliver inclusive, connected, and personalized care centered around the AD patient. By translating innovation into real-world practice, the project will reduce inequalities, support health policy, and improve outcomes for AD patients across Europe.

Who is involved

OrganisationCityCountryRole
Stichting Amsterdam UmcAmsterdamNetherlandsCoordinator
Neurimmune SubOne AGSchlierenSwitzerlandParticipant
Positrigo AGZurichSwitzerlandParticipant
Siemens Healthineers International AGZurichSwitzerlandThird party
Societe Des Produits Nestle SAVeveySwitzerlandParticipant
Fakultni Nemocnice Motol a HomolkaPraha 5CzechiaParticipant
Anavex Germany GmbHPlaneggGermanyParticipant
Deutsches Zentrum Fur Neurodegenerative Erkrankungen eVBonnGermanyParticipant
Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eVMunchenGermanyParticipant
Klinikum Der Ludwig-Maximilians-Universitat MunchenMunchenGermanyThird party
Ludwig-Maximilians-Universitaet MuenchenPlaneggGermanyParticipant
Neotiv GmbHMagdeburgGermanyParticipant
Siemens Healthcare Diagnostics Products GmbHMarburgGermanyThird party
Siemens Healthineers AGForchheimGermanyParticipant
Universitatsklinikum ErlangenErlangenGermanyParticipant
Ethniko Kentro Erevnas Kai Technologikis AnaptyxisThermi ThessalonikiGreeceParticipant
Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I SunyerBarcelonaSpainParticipant
Hospital Clinic De BarcelonaBarcelonaSpainThird party
Siemens Healthcare SLMadridSpainThird party
Universidad De NavarraPamplonaSpainParticipant
Pohjois-Savon HyvinvointialueKuopioFinlandParticipant
Siemens Healthcare Private LimitedVikhroli EastIndiaAssociatedpartner
Alzheimer EuropeSenningerbergLuxembourgParticipant
Amsterdam Umc Research BVAmsterdamNetherlandsThird party
Stichting International Registry for Alzheimers Disease and Other Dementias FoundationDeventerNetherlandsParticipant
Helse Stavanger HfStavangerNorwayParticipant
Karolinska InstitutetStockholmSwedenParticipant
Region StockholmStockholmSwedenParticipant
Eisai LimitedHatfieldUnited KingdomParticipant
King's College LondonLondonUnited KingdomParticipant
Muhdo Health LtdIpswichUnited KingdomParticipant
National Institute for Health and Care ExcellenceManchesterUnited KingdomParticipant
Siemens Healthcare LimitedCamberleyUnited KingdomAssociatedpartner
University College LondonLondonUnited KingdomParticipant
University of LeicesterLeicesterUnited KingdomParticipant
Gates Ventures LlcKirklandUnited StatesParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI